1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013 Feb;105(3):175-201. https://doi.org/10.1093/jnci/djs491. [ DOI] [ PubMed] 2. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016 Jul;65(26):661-66. https://doi.org/10.15585/mmwr.mm6526a1. [ DOI] [ PubMed] 3. Jouya S, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee DY. Cervical Cancer Epidemiology: Global Incidence, Mortality, Survival, Risk Factors, and Equity in HPV Screening and Vaccination. J Clin Med. 2026;15(3):1079. https://doi.org/10.3390/jcm15031079. [ Link] [ DOI] 4. Williamson AL. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. 2023 Jun;15(7):1440. https://doi.org/10.3390/v15071440. [ DOI] [ PubMed] 5. Ma X, Yang M. The correlation between high-risk HPV infection and precancerous lesions and cervical cancer. Am J Transl Res. 2021 Sep;13(9):10830-10836. [ PubMed] 6. Cho EH, Park MS, Woo HY, Park H, Kwon MJ. Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening. J Gynecol Oncol. 2024 Nov;35(6):e72. https://doi.org/10.3802/jgo.2024.35.e72. [ DOI] [ PubMed] 7. Wang J, Elfström KM, Dillner J. Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden. Lancet Public Health. 2024 Nov;9(11):e886-e895. https://doi.org/10.1016/s2468-2667(24)00218-4. [ DOI] [ PubMed] 8. Massad LS, Clarke MA, Perkins RB, Garcia F, Chelmow D, Cheung LC, et al. Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines. J Low Genit Tract Dis. 2025 Apr;29(2):134-43. https://doi.org/10.1097/lgt.0000000000000865. [ DOI] [ PubMed] 9. Zhang J, Wang H, Liu Y, Li Z, Feng X, Luo X, et al. HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China. J Clin Microbiol. 2026 Mar;64(3):e0128925. https://doi.org/10.1128/jcm.01289-25. [ DOI] [ PubMed] 10. Abi-Raad R, Sun T, Krishnamurti U. Human papillomavirus genotype distribution and its correlation with intraepithelial neoplasia, vaccination, and ethnicity. J Am Soc Cytopathol. 2025 Jul-Aug;14(4):273-78. https://doi.org/10.1016/j.jasc.2025.03.006. [ DOI] [ PubMed] 11. Mousavi A, Akhavan S, Sabzi shahrbabaki F, Izadi-mood N, Yarandi F, Ghazimoghadam M, et al. Assessment of the Diagnostic Value of High-Risk HPV Molecular-based Methods for Triage of Iranian Women with Abnormal Cytological Findings of ASC-US and LSIL. J Obstet Gynecol Cancer Res. 2022;7(3):151-57. https://doi.org/10.30699/jogcr.7.3.151. [ Link] [ DOI] 12. Kasraei S, Ghahghaei-Nezamabadi A, Seifollahi A, Aghajani F, Nakhostin-Ansari A, Zarei N, et al. Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups. Arch Gynecol Obstet. 2022 Sep;306(3):857-63. https://doi.org/10.1007/s00404-022-06444-0. [ DOI] [ PubMed] 13. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-31. https://doi.org/10.1097/lgt.0000000000000525. [ DOI] [ PubMed] 14. Bhogireddy V, Roston A, Chor J, Tilmon S, Mackevicius T, Keith LG, et al. Cervical intraepithelial neoplasia and cancer in women 35 years and older. J Low Genit Tract Dis. 2014 Jan;18(1):41-45. https://doi.org/10.1097/lgt.0b013e31828e831d. [ DOI] [ PubMed] 15. Tao L, Han L, Li X, Gao Q, Pan L, Wu L, et al. Prevalence and risk factors for cervical neoplasia: a cervical cancer screening program in Beijing. BMC Public Health. 2014 Nov;14:1185. https://doi.org/10.1186/1471-2458-14-1185. [ DOI] [ PubMed] 16. Teixeira NC, Araújo AC, Correa CM, Lodi CT, Lima MI, Carvalho Nde O, et al. Prevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women. Braz J Infect Dis. 2012 Mar-Apr;16(2):164-69. https://doi.org/10.1016/s1413-8670(12)70299-4. [ DOI] [ PubMed] 17. Chen Q, Quan J, Zhu K, Lan L, Lu J, Zhu L, et al. Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years. Nat Commun. 2026 Jan;17(1):1677. https://doi.org/10.1038/s41467-026-68379-3. [ DOI] [ PubMed] 18. Jia M, Lan C, Niu J, Liang Y. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 following conization. Medicine (Baltimore). 2022 Oct;101(43):e31368. https://doi.org/10.1097/md.0000000000031368. [ DOI] [ PubMed] 19. Ye Y, Li M, Yang W, Xu J, Wang X, Ma Y, et al. Characteristics of high-risk HPV infection in women with vaginal intraepithelial neoplasia in Beijing, China. J Med Virol. 2023 Dec;95(12):e29267. https://doi.org/10.1002/jmv.29267. [ DOI] [ PubMed] 20. Yalcin N, Alci A, Gokkaya M, Goksu M, Toptas T, Ureyen I. Evaluation of the Outcomes of Patients Undergoing Colposcopy for High-Risk Human Papillomavirus Positivity and/or Abnormal Cervical Cytology. Diagnostics (Basel). 2026 Feb;16(3):465. https://doi.org/10.3390/diagnostics16030465. [ DOI] [ PubMed] |
